Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
GAITHERSBURG, Md., May 30, 2018 (GLOBE NEWSWIRE) -- NexImmune, an emerging leader in the field of antigen-directed immunotherapy, today announced that the company will be participating in the...
-
Scott Carmer appointed Chief Executive OfficerKristi Jones promoted to Chief Operating OfficerAlan Roemer appointed Chairman of the Board of Directors GAITHERSBURG, Md., March 27, 2018 (GLOBE...
-
Series A financing co-led by ArrowMark Partners and Barer & Son CapitalFinancing supports initiation of Phase I/II trial of AIMTM ACT in relapsed/refractory Hematologic Malignancies in 2018 ...
-
GAITHERSBURG, Md., Oct. 17, 2017 (GLOBE NEWSWIRE) -- NexImmune and The Leukemia & Lymphoma Society (LLS) have entered a partnership to advance the Company’s novel cellular immunotherapy into...
-
GAITHERSBURG, Md., Feb. 14, 2017 (GLOBE NEWSWIRE) -- NexImmune, a biopharmaceutical company developing novel immuno-therapeutics based on the Artificial Immune (AIM™) nanotechnology platform, today...